More Than Medicine: The Hope, Hurdles, and Hidden Costs of IgG Therapy [0.03%]
超越药物：免疫球蛋白治疗的希望、障碍和隐性成本
Christopher Boldt,Huifang Lu
Christopher Boldt
Prevalence of Molecular Mutations in Non-Small Cell Lung Cancer and Current Treatment Approaches in the MENA Region: Systematic Review and Expert Opinion [0.03%]
中东和北非地区非小细胞肺癌分子突变的流行率及当前治疗方法：系统评价与专家意见
AbdulAziz AlJassim,Aladdin Kanbour,Fathi Azribi et al.
AbdulAziz AlJassim et al.
Over the past decade, the discovery of immunotherapy and targeted therapy has set new standards for the management of advanced non-small cell lung cancer (NSCLC). This study aims to investigate the prevalence of ALK, EGFR, KRAS, ROS1, MET, ...
Exceptional Response in a Patient with mRCC Through Precision-Guided Treatment Involving Immunotherapy Rechallenge with Temsirolimus and Bevacizumab [0.03%]
基于精准医疗的免疫治疗复发性肾癌的特异疗效案例报告及机制分析：阿西替尼、帕博利珠单抗、替西罗莫司和贝伐单抗的二次挑战疗法有效
Ashkan Adibi,Ünal Metin Tokat,Esranur Aydın et al.
Ashkan Adibi et al.
Comprehensive genomic profiling (CGP) and the subsequent discussions in molecular tumor boards (MTBs) are becoming an integral part of personalized cancer care. The patient with metastatic renal cell carcinoma (mRCC) presented here demonstr...
Anti-PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time? [0.03%]
抗PD-1疗法治疗晚期胆管癌：准备就绪了吗？
Gagandeep Brar,Rachna T Shroff
Gagandeep Brar
Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle? [0.03%]
塞利尼索治疗脉络膜黑色素瘤：一线希望还是一道障碍？
Carlos Ayala de Miguel,Roberto Borea,Christian Rolfo
Carlos Ayala de Miguel
Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer [0.03%]
用于DNA损伤修复异常和生化复发性前列腺癌患者的奥拉帕利联合度伐利尤单抗治疗
Karen A Autio,Deaglan J McHugh,Dana E Rathkopf et al.
Karen A Autio et al.
Antibody-Drug Conjugate-Induced Pneumonitis: A Growing Threat [0.03%]
抗体偶联物所致肺毒性的临床表现、机制和治疗展望：一个日益增长的威胁？
Kathy L Chan,Saadia A Faiz,Ajay Sheshadri
Kathy L Chan
PD-L1 Testing, Treatment Patterns, and Clinical Outcomes Among Patients with Metastatic NSCLC at an Academic Medical Center, 2017-2021 [0.03%]
2017年至2021年学术医学中心转移性非小细胞肺癌患者的PD-L1检测、治疗模式和临床结局
Mehmet Altan,Dawen Sui,Cai Xu et al.
Mehmet Altan et al.
Introduction: Targeted therapies and immune checkpoint inhibitors (ICIs) have revolutionized the management of metastatic non-small cell lung cancer (NSCLC) over the past decade. ...